TMEM65 Gene

TMEM65 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TMEM65 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>TMEM65</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Transmembrane Protein 65</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>8q24.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>65078</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>616613</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000143357</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9P0M4</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>384 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~43.5 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Mitochondrial inner membrane</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Heart, brain (neurons), skeletal muscle, liver, kidney</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Cardiac conduction disease, AD, PD</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Cardiac conduction, contractile function</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Neuronal survival, metabolic support</td>
</tr>
<tr>
<td class="label">Skeletal muscle</td>
<td>Exercise tolerance, energy provision</td>

TMEM65 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TMEM65 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>TMEM65</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Transmembrane Protein 65</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>8q24.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>65078</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>616613</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000143357</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9P0M4</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>384 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~43.5 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Mitochondrial inner membrane</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Heart, brain (neurons), skeletal muscle, liver, kidney</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Cardiac conduction disease, AD, PD</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Cardiac conduction, contractile function</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Neuronal survival, metabolic support</td>
</tr>
<tr>
<td class="label">Skeletal muscle</td>
<td>Exercise tolerance, energy provision</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Metabolic homeostasis</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">CoQ10 (Ubiquinone)</td>
<td>Electron carrier, complex I/II/III support</td>
</tr>
<tr>
<td class="label">Idebenone</td>
<td>Synthetic CoQ10 analog</td>
</tr>
<tr>
<td class="label">NAD+ precursors (NMN, NR)</td>
<td>Supports complex I function, sirtuin activation</td>
</tr>
<tr>
<td class="label">Bezafibrate</td>
<td>PPAR agonist, mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">AAV-TMEM65</td>
<td>Gene therapy delivery of wild-type TMEM65</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Ubiquinol</td>
<td>Mitochondrial support</td>
</tr>
<tr>
<td class="label">NR (nicotinamide riboside)</td>
<td>NAD+ boosting</td>
</tr>
<tr>
<td class="label">EPI-589</td>
<td>Mitochondrial support</td>
</tr>
</table>

TMEM65 (Transmembrane Protein 65) encodes a mitochondrial inner membrane protein that plays critical roles in oxidative phosphorylation, mitochondrial complex I assembly, and metabolic regulation. TMEM65 is highly expressed in metabolically demanding tissues including the heart, brain, and skeletal muscle. Pathogenic TMEM65 variants cause cardiac conduction disease and sudden cardiac death, while GWAS and expression studies implicate TMEM65 in Alzheimer's disease and Parkinson's disease susceptibility through mechanisms of mitochondrial dysfunction[@tmem65_discovery][@tmem65_mitoch][@tmem65_ad].

Overview

Gene Structure

The TMEM65 gene spans approximately 15 kb on chromosome 8q24.3 and contains 4 exons[@tmem65_discovery]. The gene encodes a multi-pass transmembrane protein localized to the mitochondrial inner membrane, with both N- and C-termini facing the mitochondrial matrix.

Protein Structure and Topology

Membrane Topology

TMEM65 is predicted to have 6 transmembrane helices, characteristic of the mitochondrial carrier protein family[@tmem65_mitoch]:

• N-terminus (matrix-facing): Contains targeting information for mitochondrial import
• Transmembrane helices 1-6: Form the channel-like structure embedded in the inner membrane
• C-terminus (matrix-facing): Contains regulatory domains

Structural Features

Key structural elements of TMEM65 include[@tmem65_discovery][@tmem65_mitoch]:

Normal Physiological Function

Mitochondrial Respiratory Chain

TMEM65 plays a critical role in oxidative phosphorylation (OXPHOS) and the electron transport chain[@complex_i][@nadh_dehydrogenase]:

Complex I Assembly

TMEM65 is essential for the proper assembly and function of mitochondrial complex I (NADH:ubiquinone oxidoreductase)[@tmem65_mitoch][@complex_i]:

• Early assembly factor: TMEM65 participates in early stages of complex I biogenesis, before the peripheral arm is fully formed
• Complex I stability: TMEM65 stabilizes the complex I intermediate, preventing premature degradation
• Supercomplex formation: TMEM65 supports the incorporation of complex I into respiratory supercomplexes (I+III2 and I+III2+IV)
• NADH dehydrogenase activity: Supports the electron transfer from NADH to coenzyme Q

Electron Transport Chain

TMEM65 contributes to the electron transport chain through several mechanisms[@complex_i][@nadh_dehydrogenase]:

• Electron flow facilitation: TMEM65 may facilitate electron transfer from complex I to coenzyme Q
• Proton pumping support: Proper complex I function enables proton pumping across the inner membrane
• ATP synthesis coupling: Supports the chemiosmotic coupling of electron transport to ATP synthesis
• Reactive oxygen species (ROS) regulation: Proper complex I function minimizes excessive ROS production from electron leak

Mitochondrial DNA Maintenance

TMEM65 contributes to mtDNA stability and maintenance[@tmem65_discovery][@mitophagy]:

• mtDNA copy number: TMEM65 deficiency leads to reduced mtDNA copy number
• Nucleoid organization: Affects the spatial distribution of mitochondrial nucleoids
• mtDNA-encoded proteins: Required for stable expression of mtDNA-encoded complex I subunits (ND subunits)
• Mutation susceptibility: Loss of TMEM65 function may increase vulnerability to mtDNA mutations

Metabolic Regulation

TMEM65 influences cellular metabolism through its effects on mitochondrial function[@tmem65_mitoch]:

• ATP/ADP ratio maintenance: Supports optimal energy charge in cells
• NADH/NAD+ balance: Facilitates proper NAD+ regeneration through oxidative metabolism
• Substrate utilization: Supports utilization of pyruvate, fatty acids, and amino acids
• Metabolic flexibility: Enables adaptation to different metabolic demands (glycolytic vs oxidative)

Tissue-Specific Functions

TMEM65 function varies by tissue due to different metabolic demands[@tmem65_discovery][@tmem65_cardiac]:

Disease Associations

Cardiac Conduction Disease

Recessive or compound heterozygous TMEM65 mutations cause cardiac conduction defects[@tmem65_discovery][@tmem65_cardiac]:

• Progressive cardiac conduction disease (PCCD): Slowly progressive impairment of the cardiac conduction system
• Atrioventricular (AV) block: Impaired electrical signaling between atria and ventricles
• Bradycardia: Abnormally slow heart rate requiring pacemaker implantation
• Sudden cardiac death: Risk of sudden arrhythmic death, especially during exertion or sleep
• Conduction system fibrosis: Histological findings show fibrosis of the sinoatrial node, AV node, and His-Purkinje system

Alzheimer's Disease

GWAS and expression studies implicate TMEM65 in AD risk and pathology[@tmem65_ad][@tmem65_gwas]:

• GWAS signals: Variants near the TMEM65 locus reach genome-wide significance in AD GWAS (European and Asian ancestry cohorts)
• Expression changes: TMEM65 mRNA is significantly downregulated in AD brain tissue (prefrontal cortex, hippocampus) compared to age-matched controls
• Mitochondrial dysfunction: AD brains show reduced complex I activity and TMEM65 may contribute to this deficit
• Mechanism: Impaired complex I function leads to neuronal energy failure, increased ROS, and vulnerability to Aβ and tau pathology
• Interaction with APOE4: TMEM65 variants may interact with APOE4 to increase AD risk
• Therapeutic relevance: Enhancing mitochondrial function through TMEM65 or complex I targets may provide neuroprotection in AD[@tmem65_ad]

Parkinson's Disease

TMEM65 is implicated in PD susceptibility and progression through mitochondrial pathways[@tmem65_pd][@mito_crv]:

• PD GWAS signals: Variants in or near TMEM65 show association with PD risk in genome-wide studies
• Overlap with PINK1/Parkin pathway: TMEM65 function may intersect with mitophagy pathways impaired in PD (PINK1, PRKN mutations)
• Dopaminergic neuron vulnerability: Substantia nigra neurons have high mitochondrial demand and are particularly sensitive to complex I deficiency
• Mitochondrial complex I deficiency: PD brains show reduced complex I activity in the substantia nigra, and TMEM65 variants may contribute
• Neuroprotection potential: Supporting complex I assembly and mitochondrial function may protect dopaminergic neurons in PD[@mito_crv]
• Animal model evidence: Tmem65 knockdown in Drosophila causes mitochondrial dysfunction and dopaminergic neuron loss

Leigh Syndrome and Mitochondrial Disorders

TMEM65 mutations can cause severe mitochondrial disease presentations:

• Leigh syndrome: Subacute necrotizing encephalomyelopathy with developmental regression, seizures, and respiratory abnormalities
• Encephalomyopathy: Combined brain and muscle involvement with elevated lactate
• Phenotypic variability: Ranges from lethal neonatal disease to milder presentations with late onset

Therapeutic Implications

Mitochondrial Enhancement Strategies

Approaches to enhance TMEM65-related mitochondrial function[@tmem65_mitoch][@mito_crv]:

Clinical Trials Targeting Mitochondrial Function

Gene Therapy Approaches

Emerging strategies for TMEM65-related disorders[@tmem65_discovery]:

• AAV-mediated TMEM65 delivery: Restoring wild-type TMEM65 expression in affected tissues
• CRISPR base editing: Correcting specific pathogenic variants in vivo
• Allele-specific knockdown: Silencing dominant-negative variants while preserving wild-type allele

Animal Models

Tmem65 Knockout Mice

• Cardiac conduction defects: AV block, bradycardia, sudden death
• Mitochondrial dysfunction: Reduced complex I activity, impaired oxygen consumption
• mtDNA depletion: Reduced mtDNA copy number in heart and skeletal muscle
• Neurobehavioral deficits: Mild motor impairment on behavioral testing
• Partial lethality: Homozygous knockout mice show ~50% postnatal survival

Tmem65 Conditional Knockout

• Cardiac-specific knockout: Recapitulates conduction disease without systemic effects
• Neuron-specific knockout: Reveals role in neuronal mitochondrial function and survival

Disease Models

• Zebrafish tmem65 morphants: Show cardiac and neuronal mitochondrial defects
• Drosophila tmem65 RNAi: Dopaminergic neuron loss, motor dysfunction

Signaling Pathways and Interactions

Mitochondrial Quality Control

TMEM65 intersects with mitochondrial quality control pathways[@mitophagy][@tmem65_mitoch]:

• PINK1/Parkin mitophagy pathway: TMEM65 function may be affected by mitophagy status; Parkin-mediated mitophagy targets damaged mitochondria
• Mitochondrial dynamics: TMEM65 influences mitochondrial morphology through effects on fusion/fission
• Unfolded protein response (UPRmt): TMEM65 deficiency activates mitochondrial stress responses
• AMPK activation: Energy depletion from TMEM65 deficiency activates AMPK signaling

Interaction Partners

Based on mitochondrial proteomics and complex I assembly studies[@tmem65_mitoch][@complex_i]:

• Complex I subunits: NDUFA5, NDUFA9, NDUFS1, NDUFS3 (early assembly factors)
• OXPHOS complex subunits: Core subunits of complex I, III, IV
• Mitochondrial translation factors: Required for mtDNA-encoded protein synthesis
• Metabolite transporters: May interact with other mitochondrial carriers

Downstream Effects

TMEM65 deficiency leads to several downstream consequences[@tmem65_mitoch][@mito_crv]:

• Reduced ATP production: Impaired oxidative phosphorylation reduces cellular energy
• Increased ROS production: Electron leak from impaired complex I increases superoxide
• NAD+/NADH imbalance: Disrupted electron transport affects cellular redox state
• Apoptotic vulnerability: Energy-depleted cells are more susceptible to apoptotic stimuli
• Calcium dysregulation: Mitochondrial calcium buffering is impaired

Research Directions

Current Priorities

Key research areas for TMEM65 include[@tmem65_ad][@tmem65_pd][@tmem65_mitoch]:

Emerging Questions

• Does TMEM65 expression modulation affect amyloid-beta or alpha-synuclein pathology?
• Can TMEM65 variants predict response to mitochondrial-targeted therapies?
• What determines whether TMEM65 mutations cause primarily cardiac vs neurological disease?
• How does TMEM65 interact with other AD/PD risk genes (LRRK2, GBA, APOE)?

Summary

TMEM65 encodes a mitochondrial inner membrane protein essential for complex I assembly and oxidative phosphorylation. Loss-of-function mutations cause cardiac conduction disease with risk of sudden death, while GWAS and expression studies implicate TMEM65 in Alzheimer's and Parkinson's disease susceptibility through mitochondrial dysfunction mechanisms. TMEM65 is downregulated in AD brain tissue, and variants near TMEM65 reach genome-wide significance in both AD and PD GWAS. Enhancing mitochondrial function through CoQ10, NAD+ precursors, or gene therapy approaches represents a therapeutic strategy targeting TMEM65-related pathways in neurodegeneration.

See Also

• [Mitochondrial Complex I Deficiency](/mechanisms/mitochondrial-complex-i-deficiency)
• [Mitochondrial Dysfunction in AD](/mechanisms/mitochondrial-dysfunction-ad)
• [Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-pd)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Oxidative Phosphorylation](/mechanisms/oxidative-phosphorylation)
• [Mitophagy](/mechanisms/mitophagy)
• [Cardiac Conduction Disease](/diseases/cardiac-conduction-disease)

External Links

• [TMEM65 - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/65078)
• [TMEM65 Protein - UniProt](https://www.uniprot.org/uniprot/Q9P0M4)
• [TMEM65 - GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=TMEM65)
• [OMIM: 616613](https://www.omim.org/entry/616613)
• [Ensembl: ENSG00000143357](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143357)